Tag
A large Harvard study finds that frequent ejaculation—about 21 times a month—is associated with a significantly reduced risk of prostate cancer among men, offering new insights into modifiable factors for prevention.
A multidisciplinary Chinese team has developed an AI-driven MRI-pathology foundation model that enables accurate, non-invasive diagnosis and grading of prostate cancer, significantly improving clinical decision-making and reducing unnecessa
A large Harvard study shows men ejaculating 21+ times monthly have a significantly reduced overall risk of prostate cancer, especially low-risk forms, across different life stages.
Statin exposure is linked to improved overall survival in prostate cancer patients treated with apalutamide but raises the risk of severe cardiac adverse events due to underlying cardiovascular conditions.
ArteraAI Prostate, the first FDA-approved AI-driven multimodal software, offers personalized clinical decision support for localized prostate cancer, improving treatment precision and reducing overtreatment risks.
KEYNOTE-991 shows pembrolizumab does not improve progression-free or overall survival for mHSPC, and increases serious adverse events when added to enzalutamide and ADT.
Treatment for advanced prostate cancer has advanced significantly in the past decade, but metastatic castration-resistant...
The PACE-C phase 3 trial shows that stereotactic body radiotherapy (SBRT) and moderately hypofractionated radiotherapy (MHRT) have comparable early toxicity profiles in intermediate- and high-risk prostate cancer patients.
Recent large RCTs show metformin does not improve survival or reduce metabolic syndrome risk in prostate cancer patients on ADT, though it modestly improves metabolic parameters.
